Recovering Together: Building Resiliency in Dyads of Patients Admitted to the Neuroscience Intensive Care Unit (NICU) and Their Caregivers
| Tracking Information | |||
|---|---|---|---|
| First Submitted Date ICMJE | September 28, 2018 | ||
| First Posted Date ICMJE | October 3, 2018 | ||
| Last Update Posted Date | October 4, 2018 | ||
| Actual Study Start Date ICMJE | October 1, 2018 | ||
| Estimated Primary Completion Date | August 31, 2020 (Final data collection date for primary outcome measure) | ||
| Current Primary Outcome Measures ICMJE |
Feasibility of recruitment (ability to recruit dyads)[ Time Frame: Baseline ] Feasibility of recruitment will be determined by reporting number of dyads Number dyads who agree to participate Feasibility of intervention delivery (ability to delivery intervention to dyads)[ Time Frame: Feasibility of program delivery will be measured at 6 weeks ] Number of dyads who complete the post-intervention assessment. Credibility and expectancy questionnaire[ Time Frame: Baseline ] This measure will assess participants' belief that the intervention (or control) will be helpful. Client Satisfaction Questionnaire[ Time Frame: post intervention (6 weeks after baseline) ] This measure will assess participants' satisfaction with participation in the study. |
||
| Original Primary Outcome Measures ICMJE | Same as current | ||
| Current Secondary Outcome Measures ICMJE |
|
||
| Descriptive Information | |||
| Brief Title ICMJE | Recovering Together: Building Resiliency in Dyads of Patients Admitted to the Neuroscience Intensive Care Unit (NICU) and Their Caregivers |
||
| Official Title ICMJE | Recovering Together: Building Resiliency in Dyads of Patients Admitted to the Neuroscience Intensive Care Unit (NICU) and Their Caregivers |
||
| Brief Summary | The investigators will compare a dyadic intervention (Recovering Together) with an attention placebo educational control in dyads of patients with acute neurological illnesses and their caregivers at risk for chronic emotional distress. The primary aim of this study is to determine the feasibility, credibility, and satisfaction with Recovering Together. The second aim is to show proof of concept for sustained improvement in emotional distress, post traumatic stress (PTS), resiliency and interpersonal communication outcomes in patients and caregivers. |
||
| Detailed Description | The investigators aim to improve the care of patients (pts) admitted to the Neuroscience Intensive Care Unit (NICU) and their family caregivers (cgs) by conducting a pilot feasibility randomized controlled trial (RCT; N=80 dyads; 60 completers) of the dyadic resiliency program ("Recovering Together") to prevent chronic emotional distress in both pts and their cgs. Eligible dyads include adult, English speaking pts with acute neurological injury (ANI) admitted to the NICU, cleared medically and cognitively for participation by the nursing team, and their primary cgs. Dyads who are randomly assigned to "Recovering Together" will receive 6 manualized sessions (2 in person at hospitalization and 4 through live video after discharge, to reduce burden and facilitate access to care) led by a clinical psychologist. Dyads who are randomly assigned to the attention placebo educational control condition will receive 6 manualized sessions (2 in person and 4 through live video with a clinical psychologist), modeled after the Recovering Together program that will control for the dose of the intervention and support from therapist. Dyads will complete assessment surveys before, after the intervention and 3 months later. Clinical data on demographics, diagnosis, ANI severity, and any medical complications will be extracted from electronic health records. | ||
| Study Type ICMJE | Interventional | ||
| Study Phase | N/A | ||
| Study Design ICMJE | Allocation: Randomized Intervention Model: Parallel Assignment Intervention Model Description: Masking: Interventional Masking Description: Primary Purpose: Prevention |
||
| Condition ICMJE | |||
| Intervention ICMJE |
|
||
| Study Arms |
|
||
| Recruitment Information | |||
| Recruitment Status ICMJE | Not yet recruiting | ||
| Estimated Enrollment ICMJE |
160 | ||
| Original Estimated Enrollment ICMJE | Same as current | ||
| Estimated Study Completion Date | August 31, 2020 | ||
| Estimated Primary Completion Date | August 31, 2020 (Final data collection date for primary outcome measure) | ||
| Eligibility Criteria ICMJE | Inclusion Criteria: - Male and female out patients, age 50 years or older - Have a nonmalignant chronic pain for more than 3 months - Has a documented MCI diagnosed by a neurologist - Able to perform a 6-minute walk test - Free of concurrent psychotropic or pain medication for at least 2 weeks prior to initiation of treatment, OR stable on current psychotropic or pain medication for a minimum of 6 weeks and willing to maintain a stable dose - Cleared by a medical doctor for study participation Exclusion Criteria: - Diagnosed with a medical illness expected to worsen in the next 6 months (e.g. malignancy) - Serious mental illness or instability for which hospitalization may be likely in the next 6 months - Current suicidal ideation reported on self-report - Lifetime history of schizophrenia, bipolar disorder, or other psychotic disorder - Current substance abuse or dependence and current substance use disorder, within the past 6 months - Practice of yoga/meditation, or other mind body techniques that elicit the RR, once per week for 45 minutes or more within the last 3 months or less - Regular use of Fitbit in the last 3 months - Unable to walk without use of assistance (e.g. walk, cane, wheelchair) | ||
| Sex/Gender |
|
||
| Ages | 18 Years and older (Adult, Older Adult) | ||
| Accepts Healthy Volunteers | No | ||
| Listed Location Countries ICMJE | United States | ||
| Removed Location Countries | |||
| Administrative Information | Has Data Monitoring Committee | No | |
| U.S. FDA-regulated Product |
Studies a U.S. FDA-regulated Drug Product: No Studies a U.S. FDA-regulated Device Product: No |
||
| IPD Sharing Statement |
|
||
| Responsible Party | Ana-Maria Vranceanu, PhD,Massachusetts General Hospital | ||
| Study Sponsor ICMJE | Massachusetts General Hospital | ||
| Collaborators ICMJE | |||
| Investigators ICMJE |
|
||
| PRS Account | Massachusetts General Hospital | ||
| Verification Date | October 2018 | ||
|
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |
|||

